173 related articles for article (PubMed ID: 36965100)
1. A Cascade-Targeted Enzyme-Instructed Peptide Self-Assembly Strategy for Cancer Immunotherapy through Boosting Immunogenic Cell Death.
Xie L; Ding Y; Zhang X; Zhang Z; Zeng S; Wang L; Yang Z; Liu Q; Hu ZW
Small Methods; 2023 May; 7(5):e2201416. PubMed ID: 36965100
[TBL] [Abstract][Full Text] [Related]
2. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
[TBL] [Abstract][Full Text] [Related]
3. Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death.
Zheng D; Liu J; Xie L; Wang Y; Ding Y; Peng R; Cui M; Wang L; Zhang Y; Zhang C; Yang Z
Acta Pharm Sin B; 2022 Jun; 12(6):2740-2750. PubMed ID: 35755291
[TBL] [Abstract][Full Text] [Related]
4. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
5. Self-reinforced photodynamic immunostimulator to downregulate and block PD-L1 for metastatic breast cancer treatment.
Qiu Z; Lu Z; Huang J; Zhong Y; Yan N; Kong R; Cheng H
Biomaterials; 2023 Dec; 303():122392. PubMed ID: 37984245
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
7. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
[TBL] [Abstract][Full Text] [Related]
8. Tumor Selective Metabolic Reprogramming as a Prospective PD-L1 Depression Strategy to Reactivate Immunotherapy.
Liu Y; Zhou Z; Hou J; Xiong W; Kim H; Chen J; Zheng C; Jiang X; Yoon J; Shen J
Adv Mater; 2022 Oct; 34(41):e2206121. PubMed ID: 36017886
[TBL] [Abstract][Full Text] [Related]
9. Bioactive Peptide Nanodrugs Based on Supramolecular Assembly for Boosting Immunogenic Cell Death-Induced Cancer Immunotherapy.
Liu Y; Chang R; Xing R; Yan X
Small Methods; 2023 May; 7(5):e2201708. PubMed ID: 36720041
[TBL] [Abstract][Full Text] [Related]
10. Targeted Enrichment of Enzyme-Instructed Assemblies in Cancer Cell Lysosomes Turns Immunologically Cold Tumors Hot.
Ji S; Li J; Duan X; Zhang J; Zhang Y; Song M; Li S; Chen H; Ding D
Angew Chem Int Ed Engl; 2021 Dec; 60(52):26994-27004. PubMed ID: 34643312
[TBL] [Abstract][Full Text] [Related]
11. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy.
Song S; Shim MK; Yang S; Lee J; Yun WS; Cho H; Moon Y; Min JY; Han EH; Yoon HY; Kim K
Bioact Mater; 2023 Oct; 28():358-375. PubMed ID: 37334068
[TBL] [Abstract][Full Text] [Related]
12. MMP-2 Responsive Peptide Hydrogel-Based Nanoplatform for Multimodal Tumor Therapy.
Zhang Q; Hu W; Guo M; Zhang X; Zhang Q; Peng F; Yan L; Hu Z; Tangthianchaichana J; Shen Y; Hu H; Du S; Lu Y
Int J Nanomedicine; 2024; 19():53-71. PubMed ID: 38187906
[TBL] [Abstract][Full Text] [Related]
13. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
Dai X; Meng J; Deng S; Zhang L; Wan C; Lu L; Huang J; Hu Y; Zhang Z; Li Y; Lovell JF; Wu G; Yang K; Jin H
Theranostics; 2020; 10(7):3049-3063. PubMed ID: 32194854
[TBL] [Abstract][Full Text] [Related]
14. EISA in Tandem with ICD to Form In Situ Nanofiber Vaccine for Enhanced Tumor Radioimmunotherapy.
Luo H; Cao H; Jia H; Shang Y; Liu J; Gui H; Yang C; Ren C; Wang Z; Liu J
Adv Healthc Mater; 2023 Oct; 12(27):e2301083. PubMed ID: 37300544
[TBL] [Abstract][Full Text] [Related]
15. Semiconducting Polymer Nanoparticles with Surface-Mimicking Protein Secondary Structure as Lysosome-Targeting Chimaeras for Self-Synergistic Cancer Immunotherapy.
Qi J; Jia S; Kang X; Wu X; Hong Y; Shan K; Kong X; Wang Z; Ding D
Adv Mater; 2022 Aug; 34(31):e2203309. PubMed ID: 35704513
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Intervention Liposome Boosted Lung Cancer Radio-Immunotherapy via Hypoxia Amelioration and PD-L1 Restraint.
Wang S; Zhou Z; Hu R; Dong M; Zhou X; Ren S; Zhang Y; Chen C; Huang R; Zhu M; Xie W; Han L; Shen J; Xie C
Adv Sci (Weinh); 2023 Jun; 10(18):e2207608. PubMed ID: 37092578
[TBL] [Abstract][Full Text] [Related]
17. Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade.
Li Q; Chen C; Kong J; Li L; Li J; Huang Y
Acta Pharm Sin B; 2022 May; 12(5):2533-2549. PubMed ID: 35646521
[TBL] [Abstract][Full Text] [Related]
18. Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.
Kofla G; Radecke C; Frentsch M; Walther W; Stintzing S; Riess H; Bullinger L; Na IK
Oncoimmunology; 2022; 11(1):2068109. PubMed ID: 35496500
[TBL] [Abstract][Full Text] [Related]
19. Bio-responsive Au-miR-183 inhibitor enhances immunotherapy in hepatocellular carcinoma by inducing immunogenic cell death.
Yin L; Wei Y; Liu Y; Mo X; Song J; Cai W
J Control Release; 2024 Apr; 368():498-517. PubMed ID: 38428529
[TBL] [Abstract][Full Text] [Related]
20. Integrating Enzymatic Self-Assembly and Mitochondria Targeting for Selectively Killing Cancer Cells without Acquired Drug Resistance.
Wang H; Feng Z; Wang Y; Zhou R; Yang Z; Xu B
J Am Chem Soc; 2016 Dec; 138(49):16046-16055. PubMed ID: 27960313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
